Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

[Aberrant activation mechanisms of the NOTCH signaling pathway in T lymphoblastic lymphoma: mechanisms and targeted therapeutic implications].

Created on 05 Sep 2026

Authors

Zhexin Li, Guzhengyue Zheng

Published in

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences. Pages 1-10. Aug 31, 2026. Epub Aug 31, 2026.

Abstract

T-cell lymphoblastic lymphoma (T-LBL) is a highly aggressive non-Hodgkin lymphoma derived from precursor T cells, characterized by rapid clinical progression and a high relapse rate, with a particularly unfavorable prognosis in adult patients. Accumulating evidence indicates that the NOTCH signaling pathway plays a central oncogenic role in the initiation and progression of T-LBL. Its sustained aberrant activation is driven by multiple layers of mechanisms, including NOTCH1 gene mutations or fusions, synergistic amplification through multiple oncogenic signaling cascades, and dysregulated epigenetic control. Aberrantly activated NOTCH signaling promotes tumor cell proliferation, suppresses apoptosis, and contributes to chemotherapy resistance and disease relapse. This review focuses on the mechanisms underlying aberrant NOTCH activation in T-LBL and summarizes the principal therapeutic strategies targeting this pathway, along with their limitations, aiming to provide a framework for deeper under-standing of the molecular pathogenesis of T-LBL and for the development of more precise targeted therapies.

PMID:
42695206
Bibliographic data and abstract were imported from PubMed on 05 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 14
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement